A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis
Status:
Completed
Trial end date:
2017-07-01
Target enrollment:
Participant gender:
Summary
This is a dose finding study to evaluate the safety and determine the maximum tolerated dose
of carfilzomib in patients with previously treated systemic light-chain amyloidosis.